SCHEMBL5545936

SCHEMBL5545936

[CH2]CCCCN1CCC(Oc2ccccc2)CC1

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 1/20 0.61
PRMT6 Q96LA8 1/20 0.61
DRD2 P14416 3/20 0.50
DRD4 P21917 3/20 0.50
DRD3 P35462 3/20 0.50
HTR7 P34969 3/20 0.48
HTR2A P28223 1/20 0.48
CHRM2 P08172 1/20 0.47
CHRM3 P20309 1/20 0.47
HRH3 Q9Y5N1 3/20 0.46
TMEM97 Q5BJF2 1/20 0.46
SIGMAR1 Q99720 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
GAA P10253 1/20 0.45
HRH1 P35367 1/20 0.44
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5542517 0.98 CARM1 (0.59) CARM1PRMT6DRD2DRD4DRD3
SCHEMBL5545161 0.95 CARM1 (0.62) CARM1PRMT6DRD2DRD4DRD3
SCHEMBL5537846 0.91 CARM1 (0.68) CARM1PRMT6DRD2DRD4DRD3
SCHEMBL12041235 0.84 CARM1 (0.63) CARM1PRMT6DRD2DRD4DRD3
SCHEMBL11284215 0.84 CARM1 (0.63) CARM1PRMT6DRD2DRD4DRD3
SCHEMBL30584824 0.83 CARM1 (0.62) CARM1PRMT6DRD2DRD4DRD3
SCHEMBL12041268 0.82 CARM1 (0.62) CARM1PRMT6DRD2DRD4DRD3
SCHEMBL427694 0.82 CARM1 (0.60) CARM1PRMT6DRD2DRD4DRD3
SCHEMBL5537589 0.82 ADRB2 (0.48) CARM1PRMT6HRH3
SCHEMBL19852070 0.82 SIGMAR1 (0.62) CARM1PRMT6HTR2AHRH3SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 CARM1 1867/4885PRMT6 1148/4885DRD2 542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.